

LAPAROSCOPIC GASTRIC BYPASS: Common Channel trial

No registrations found.

Ethical review	Positive opinion
Status	Recruitment stopped
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON24253

Source

NTR

Brief title

DUCATI

Health condition

Morbid Obesity, Bariatric Surgery
Morbide Obesitas, Bariatrische chirurgie

Sponsors and support

Primary sponsor: G.H.H. Mannaerts, M.D., Ph.D. Gastrointestinal surgeon

Sint Franciscus Gasthuis
Department of surgery
PO Box 3045 PM
Rotterdam, The Netherlands
T: +31-10-4616161
E: g.mannaerts@sfg.nl

Source(s) of monetary or material Support: fund = initiator = sponsor

Intervention

Outcome measures

Primary outcome

The primary endpoint is sustainable weight loss, which is expressed by the percentage Excess Weight Loss (%EWL) after a follow-up period of 1 year.

Excess weight (kg) will be calculated with the formula $EW = AW - IW$ (actual weight- ideal weight), $IW = 22 \times L^2$ (L=length in meters). The amount of weight loss will be expressed as percentage excess weight loss (%EWL), and calculated with the formula $\%EWL = (\text{pre-operative BMI} - \text{current BMI}) / (\text{pre-operative BMI} - 25) \times 100\%$.

Secondary outcome

□ Operating time, mean hospital stay, intra-operative and post-operative morbidity, and in-hospital mortality. Morbidity is defined as reoperations, reinterventions, re-admissions and serious adverse events. Morbidity is classified as major (anastomotic leakage, major peroperative blood loss due to splenic or vascular hemorrhage, pulmonary embolism, intra-abdominal abscess and intra-abdominal hematoma) or minor (wound infection, urinary tract infection and anastomotic stenosis) complications. Moreover, the rate of extra outpatient and ER visits due to complaints are recorded.

□ Improvement in obesity induced co-morbidity (DM-II, hypertension, hypercholesterolemia, OSAS and joint-pain) as defined by Moorehead

□ Patient's health-related quality of life (QoL) objectified by the MOS Short Form 36 (SF 36), Gastro-Intestinal Quality of Life Index, and Obesity related Quality of life the Moorehead-Ardelt II questionnaires and the Bariatric Analysis and Reporting Outcome System (BAROS) score.

□ Biochemical and hormonal values following DLRYGB and standard LRYGB. The following parameters will be evaluated: Vitamin B1, B6, B12, D, folic acid, HbA1C, ferritin, iron, transferrin, cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride.

Study description

Background summary

This study is designed as a prospective randomized controlled clinical trial comparing two bariatric treatment strategies for morbid obesity. Patients will be randomly allocated 1:1 to A) distal LRYGB or B) standard LRYGB and will be followed for a period of at least 1 year.

Randomisation is stratified for participating center. The study will be performed in a clinical and out-patient setting with regular visits at 2, 6, and 12 months post intervention.

The study will be set up as a multicenter study with (at least two) bariatric centers of excellence performing at least 500 bariatric procedures annually that have indicated that they are willing to participate pending ethical approval (Lievensberg Ziekenhuis Bergen op Zoom, St. Franciscus Gasthuis Rotterdam).

Study objective

A randomized controlled trial investigating the optimal common channel length in laparoscopic gastric bypass for morbid obese patients:
Distal versus Standard Laparoscopic Roux-en-Y Gastric Bypass.

Study design

2, 6, and 12 months

Intervention

Distal Laparoscopic Roux-en-Y Gastric Bypass (DLRYGB)
Standard Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)

Contacts

Public

Sint Franciscus Gasthuis

R.P.M. Gadiot
Rotterdam 3045 PM
The Netherlands
+31-10-4616161

Scientific

Sint Franciscus Gasthuis

R.P.M. Gadiot
Rotterdam 3045 PM
The Netherlands
+31-10-4616161

Eligibility criteria

Inclusion criteria

- Age 18-60 years
- BMI > 40, or >35 kg/m² with co-morbidity
- Psychological screening excluding psychiatric and psychological disorders
- Informed consent and willing to enter the follow up program after the operation.

Exclusion criteria

- Prior bariatric surgery
- Prior major abdominal surgery (like colonic resection, septic abdomen, aorta surgery, or other procedures with a high risk of intra-abdominal adhesions, which might jeopardise the possibility of performing a DLRYGB, standard LRYGB
- ASA (American Society for Anesthesiologists) classification \geq IV
- Pregnant women
- Endocrine causes, alcohol or drug abuse
- Severe concomitant disease (carcinomas, neurodegenerative disorders or other disorders presently representing being considered exclusion criteria for bariatric surgery)
- The inability of reading/understanding and filling out questionnaires
- DLRYGB or LYRGB is technically not possible as will be determined by the surgeon during surgery.

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Single blinded (masking used)
Control:	Active

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	01-03-2014
Enrollment:	444
Type:	Actual

Ethics review

Positive opinion	
Date:	17-03-2014

Application type:

First submission

Study registrations

Followed up by the following (possibly more current) registration

ID: 39011

Bron: ToetsingOnline

Titel:

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL4313
NTR-old	NTR4466
CCMO	NL43951.101.13
OMON	NL-OMON39011

Study results